YC Biotech Corporation and Xindian-Wenshan Community Health Care Group have officially joined forces to introduce EG BioMed’s DNA methylation cancer indicator testing technology to the Taiwan market. The partnership was celebrated on the 17th with a signing ceremony banquet at Su-Hang Restaurant, where both parties reaffirmed their commitment to making innovative cancer detection more widely accessible.
This cutting-edge testing method, known for its simplicity, speed, and accuracy, enhances diagnostic precision for physicians while offering a more comfortable experience for patients. By working together, the two organizations aim to bring this advanced screening technology to a broader population, improving early detection and treatment outcomes.
At the event, YC Biotech provided insight into the development of their technology, engaging in lively and productive discussions with attending medical experts. The feedback gathered will play a key role in refining the technology and expanding its practical applications in clinical settings.
YC Biotech also announced that the testing technology has been submitted for FDA certification review, with approval anticipated within the next month. A positive outcome would pave the way for wider adoption and expansion of DNA methylation testing.
The partnership marks a significant step toward advancing cancer diagnostics in Taiwan. With a shared vision for improving healthcare, YC Biotech and Xindian-Wenshan Community Health Care Group will continue working together to drive progress in medical innovation and enhance public health.